Cover Image
市場調查報告書

黑色素瘤:疾病的預測與市場分析

Melanoma Disease Coverage Forecast and Market Analysis to 2024

出版商 Datamonitor Healthcare 商品編碼 594581
出版日期 內容資訊 英文 309 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
黑色素瘤:疾病的預測與市場分析 Melanoma Disease Coverage Forecast and Market Analysis to 2024
出版日期: 2017年11月06日 內容資訊: 英文 309 Pages
簡介

根據WHO (世界衛生組織)的發表,黑色素瘤的發病數量,比其他種類的癌症都急速增加。主要的風險要素中,雖然沒包含老齡化,但是包含著生活習慣的變化,尤其是紫外線的暴露。

本報告提供黑色素瘤的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,疾病概要和背景情況,主要的推動及阻礙市場要素,現在/未來的代表性治療藥,各產品的市場趨勢預測,主要產品的簡介,在主要國家的藥價、醫療費償付制度的實情,目前臨床實驗的進展等的相關調查。

市場預測:黑色素瘤

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • binimetinib
  • Cotellic (cobimetinib)
  • encorafenib
  • Imlygic (talimogene laherparepvec)
  • Keytruda (pembrolizumab)
  • Mekinist (trametinib)
  • Opdivo (nivolumab)
  • Tafinlar (dabrafenib)
  • Yervoy (ipilimumab)
  • Zelboraf (vemurafenib)
  • 一次調查技術

治療方法:黑色素瘤

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 目前治療選擇
  • 處方藥的趨勢

流行病學:黑色素瘤

  • 摘要整理
  • 疾病的背景情況
  • 分析方法
  • 未來預測
  • 流行病學者的見解
  • 分析的優勢和弱點
  • 附錄:額外的資訊來源
  • 參考文獻

已上市醫藥品:黑色素瘤

  • 摘要整理
  • 產品概要
  • 產品簡介:Cotellic
  • 產品簡介:Imlygic
  • 產品簡介:Keytruda
  • 產品簡介:Mekinist
  • 產品簡介:Opdivo
  • 產品簡介:Tafinlar
  • 產品簡介:Yervoy
  • 產品簡介:Zelboraf

惡性黑色素瘤的治療藥的價格和醫療費償付

  • 摘要整理
  • 市場背景情況
  • 美國
  • 日本
  • 歐洲主要5個國家

開發中產品:黑色素瘤

  • 摘要整理
  • 臨床實驗開發平台概要
  • 產品簡介 (最後階段):binimetinib
  • 產品簡介 (最後階段):encorafenib
目錄
Product Code: DMKC 5786

Disease Overview:

The World Health Organization has reported that the incidence of melanoma is increasing faster than that of any other cancer in the world. Melanoma occurs when melanocytes - melanin-producing cells - become malignant. Malignancy of melanocytes in the basal layer of the skin is referred to as primary cutaneous malignant melanoma. Unlike many other common cancers, there is no significant increase in risk for the elderly; instead, the increase in incidence is likely to be due to changes in lifestyle. In particular, the amount of and susceptibility to ultraviolet exposure are key risk factors for malignant melanoma, and are driving the increase in incidence in all age groups.

Market Snapshot:

  • Immunotherapy monotherapies and combination therapies will be the main drivers of growth in the melanoma market over the forecast period.
  • The introduction of targeted therapies has substantially changed the treatment landscape of melanoma.
  • Melanoma is a common cancer in the Western world with an increasing incidence, although prognosis is highly variable.
  • Immune checkpoint inhibitors Yervoy, Opdivo, and Keytruda will be key drivers of growth in the melanoma market.
  • New developers are targeting NRAS and BRAF mutation-positive patients to distinguish their products, despite the market being limited.
  • Immunotherapies are changing melanoma treatment paradigms.

TABLE OF CONTENTS

FORECAST: MELANOMA

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • binimetinib
  • Cotellic (cobimetinib)
  • encorafenib
  • Imlygic (talimogene laherparepvec)
  • Keytruda (pembrolizumab)
  • Mekinist (trametinib)
  • Opdivo (nivolumab)
  • Tafinlar (dabrafenib)
  • Yervoy (ipilimumab)
  • Zelboraf (vemurafenib)
  • Primary Research Methodology

TREATMENT: MELANOMA

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends

EPIDEMIOLOGY: MELANOMA

  • Executive Summary
  • Disease Background
  • Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix: Additional Sources
  • Bibliography

MARKETED DRUGS: MELANOMA

  • Executive Summary
  • Product Overview
  • Product profile: Cotellic
  • Product profile: Imlygic
  • Product profile: Keytruda
  • Product profile: Mekinist
  • Product profile: Opdivo
  • Product profile: Tafinlar
  • Product profile: Yervoy
  • Product profile: Zelboraf

MALIGNANT MELANOMA PRICING AND REIMBURSEMENT

  • Executive Summary
  • Market Context
  • US
  • Japan
  • Five Major EU Markets

PIPELINE: MELANOMA

  • Executive Summary
  • Clinical Pipeline Overview
  • Product profile (late stage): binimetinib
  • Product profile (late stage): encorafenib

LIST OF FIGURES

  • Figure 1: Melanoma market forecast across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 2: Melanoma market forecast across the US, Japan, and five major EU markets, by class, 2015-24
  • Figure 3: BRAF mutation-positive melanoma market forecast across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 4: Branded melanoma market value in the US, 2015-24
  • Figure 5: Branded melanoma market value in the five major EU markets, by country, 2015-24
  • Figure 6: Branded melanoma market value in Japan, 2015-24
  • Figure 7: Methodology flow for Datamonitor Healthcare's melanoma forecast
  • Figure 8: Price sources and calculations, by country
  • Figure 9: Binimetinib sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 10: Cotellic sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 11: Encorafenib sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 12: Imlygic sales for melanoma across the US and five major EU markets, by country, 2015-24
  • Figure 13: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 14: Mekinist sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 15: Opdivo sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 16: Tafinlar sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 17: Yervoy sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 18: Zelboraf sales for melanoma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 19: Distribution of melanoma patients across the US, Japan, and five major EU markets, by stage and country
  • Figure 20: Percentage of Stage I melanoma patients receiving each type of treatment, by country
  • Figure 21: Percentage of Stage II melanoma patients receiving each type of treatment, by country
  • Figure 22: Percentage of Stage III melanoma patients without in-transit disease receiving each treatment type at first-line, by country
  • Figure 23: Percentage of Stage III melanoma patients with in-transit disease receiving each treatment type at first-line, by country
  • Figure 24: Percentage of Stage III melanoma patients without in-transit disease receiving neoadjuvant and/or adjuvant therapy at first-line, by country
  • Figure 25: Percentage of Stage III melanoma patients with in-transit disease receiving neoadjuvant and/or adjuvant therapy at first-line, by country
  • Figure 26: Top three adjuvant regimens used in the first-line treatment of Stage III melanoma patients without in-transit disease receiving pharmacological therapy with surgery, by country
  • Figure 27: Top three adjuvant regimens used in the first-line treatment of Stage III melanoma patients with in-transit disease receiving pharmacological therapy with surgery, by country
  • Figure 28: Top three neoadjuvant regimens used in the first-line treatment of Stage III melanoma patients without in-transit disease receiving pharmacological therapy with surgery, by country
  • Figure 29: Top three neoadjuvant regimens used in the first-line treatment of Stage III melanoma patients with in-transit disease receiving pharmacological therapy with surgery, by country
  • Figure 30: Percentage of Stage IV melanoma patients receiving each treatment type at first-line, by country
  • Figure 31: Percentage of Stage IV melanoma patients tested for melanoma-relevant aberrations, by country
  • Figure 32: Top three regimens used in the first-line treatment of Stage IV melanoma patients receiving pharmacological therapy without surgery, by country
  • Figure 33: MAPK-targeted regimens used in the first-line treatment of Stage IV melanoma patients receiving pharmacological therapy without surgery, by country
  • Figure 34: Percentage of Stage IV melanoma patients progressing in line of therapy, by transition and country
  • Figure 35: Top three regimens used in the second-line treatment of Stage IV melanoma, by country
  • Figure 36: Top three regimens used in the third-line treatment of Stage IV melanoma, by country
  • Figure 37: Percentage of local relapse melanoma patients receiving each treatment type at first-line, by country
  • Figure 38: Top three regimens used in the first-line adjuvant treatment of local relapse melanoma patients receiving pharmacological treatment with surgery, by country
  • Figure 39: Percentage of distant relapse melanoma patients receiving each treatment type at first-line, by country
  • Figure 40: Top three regimens used in the first-line treatment of distant relapse melanoma patients receiving pharmacological therapy without surgery, by country
  • Figure 41: Percentage of distant relapsed melanoma patients receiving additional lines of therapy, by line of therapy and country
  • Figure 42: Top three regimens used in the treatment of second-line distant relapse melanoma patients, by country
  • Figure 43: Top three regimens used in the treatment of third-line distant relapse melanoma patients, by country
  • Figure 44: Trends in incident cases of melanoma in the US, Japan, and five major EU markets, 2016-36
  • Figure 45: Age-specific trends in incident cases of melanoma in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 46: Proportion of incident cases of melanoma in the US, Japan, and five major EU markets, by AJCC stage at diagnosis and country, 2016
  • Figure 47: US incident melanoma cases, by subtype, 2016
  • Figure 48: Racial disparities in melanoma incidence, stage at diagnosis, and survival in the US, 2000-13
  • Figure 49: Racial disparities in melanoma histological subtype at diagnosis in the US, 2000-13
  • Figure 50: Cotellic in melanoma - SWOT analysis
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Cotellic for melanoma
  • Figure 52: Datamonitor Healthcare's drug assessment summary of Cotellic for melanoma
  • Figure 53: Imlygic in melanoma - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Imlygic for melanoma
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Imlygic for melanoma
  • Figure 56: Keytruda in melanoma - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary of Keytruda for melanoma
  • Figure 58: Datamonitor Healthcare's drug assessment summary of Keytruda for melanoma
  • Figure 59: Mekinist in melanoma - SWOT analysis
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Mekinist for melanoma
  • Figure 61: Datamonitor Healthcare's drug assessment summary of Mekinist for melanoma
  • Figure 62: Opdivo in melanoma - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Opdivo for melanoma
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Opdivo for melanoma
  • Figure 65: Tafinlar in melanoma - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of Tafinlar for melanoma
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Tafinlar for melanoma
  • Figure 68: Yervoy in melanoma - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of Yervoy for melanoma
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Yervoy for melanoma
  • Figure 71: Zelboraf in melanoma - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Zelboraf for melanoma
  • Figure 73: Datamonitor Healthcare's drug assessment summary of Zelboraf for melanoma
  • Figure 74: Binimetinib for melanoma - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of binimetinib in melanoma
  • Figure 76: Datamonitor Healthcare's drug assessment summary of binimetinib in melanoma
  • Figure 77: Encorafenib for melanoma - SWOT analysis
  • Figure 78: Datamonitor Healthcare's drug assessment summary of encorafenib in melanoma
  • Figure 79: Datamonitor Healthcare's drug assessment summary of encorafenib in melanoma

LIST OF TABLES

  • Table 1: Summary of drug classes and molecules included in the melanoma patient-based forecast
  • Table 2: Estimated approval dates for key late-stage pipeline products and marketed brands in melanoma, 2015-24
  • Table 3: Patent expiries occurring within the melanoma market during the forecast period, 2015-24
  • Table 4: Exchange rates used for calculating prices
  • Table 5: Binimetinib sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 6: Cotellic sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 7: Encorafenib sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 8: Imlygic sales for melanoma across the US and five major EU markets, by country ($m), 2015-24
  • Table 9: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 10: Mekinist sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 11: Opdivo sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 12: Tafinlar sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 13: Yervoy sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 14: Zelboraf sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 15: Physicians surveyed for the melanoma primary research study, 2015
  • Table 16: Physicians surveyed for the melanoma primary research study, 2017
  • Table 17: Melanoma five-year relative survival rates in the US, by stage at diagnosis, 2007-13
  • Table 18: AJCC primary tumor (T) and nodal (N) classification
  • Table 19: AJCC TNM clinical and pathological staging system for melanoma
  • Table 20: Key drugs available for the treatment of malignant melanoma
  • Table 21: Melanoma International Statistical Classification of Diseases topography codes
  • Table 22: Melanoma TNM classification, by stage at diagnosis
  • Table 23: Cancer registry databases used as a source of melanoma incidence data, by country
  • Table 24: Forecasting methodology for melanoma incidence, by country, age group, and gender
  • Table 25: Data sources used to segment incident melanoma cases by AJCC stage, by country
  • Table 26: Sources of survival data used to estimate melanoma prevalence, by country
  • Table 27: Sources of data used to estimate prevalence of biomarkers in prevalent melanoma cases, by country
  • Table 28: Incident cases of melanoma in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 29: Age- and gender-specific incident cases of melanoma in the US, Japan, and five major EU markets, by country, 2016
  • Table 30: Proportion and number of incident cases of melanoma in the US, Japan, and five major EU markets, by AJCC stage at diagnosis and country, 2016
  • Table 31: Validation of forecast estimates against benchmark estimates
  • Table 32: Key marketed drugs for melanoma
  • Table 33: Cotellic drug profile
  • Table 34: Cotellic pivotal trial data in melanoma
  • Table 35: Imlygic drug profile
  • Table 36: Imlygic pivotal trial data in melanoma
  • Table 37: Keytruda drug profile
  • Table 38: Overview of pivotal trial data for Keytruda in melanoma
  • Table 39: Keytruda ongoing clinical trials in melanoma
  • Table 40: Mekinist drug profile
  • Table 41: Mekinist pivotal trial data in melanoma
  • Table 42: Mekinist ongoing late-phase trial data in melanoma
  • Table 43: Opdivo drug profile
  • Table 44: Opdivo pivotal trial data in melanoma
  • Table 45: Opdivo late-phase clinical trial data in melanoma
  • Table 46: Opdivo ongoing late-phase clinical trials in melanoma
  • Table 47: Tafinlar drug profile
  • Table 48: Tafinlar pivotal trial data in melanoma
  • Table 49: Tafinlar ongoing late-phase clinical trials in melanoma
  • Table 50: Yervoy drug profile
  • Table 51: Yervoy pivotal trial data in melanoma
  • Table 52: Yervoy ongoing late-phase clinical trials in melanoma
  • Table 53: Zelboraf drug profile
  • Table 54: Zelboraf pivotal trial data in melanoma
  • Table 55: Zelboraf ongoing late-phase clinical trials in melanoma
  • Table 56: Marketed malignant melanoma products and approved indications in the US, Japan, and five major EU markets
  • Table 57: Late-stage candidates in development for malignant melanoma
  • Table 58: Price sources and calculations, by country
  • Table 59: Exchange rates used for calculating prices
  • Table 60: US pricing of marketed melanoma therapies
  • Table 61: Formulary placement of Mekinist, Tafinlar, and Zelboraf in selected commercial formularies
  • Table 62: Formulary placement of Mekinist, Tafinlar, and Zelboraf in top five Medicare Part D formularies
  • Table 63: Prior authorization criteria for key melanoma treatments in major health insurance plans
  • Table 64: Phase III trial data for Opdivo plus Yervoy compared to monotherapy in the first-line treatment of melanoma
  • Table 65: Phase III trial data for Keytruda compared to Yervoy in the first-line treatment of melanoma
  • Table 66: Pricing premiums given to medicines that demonstrate benefit over comparators
  • Table 67: Monthly cost of treatment (Tafinlar and Zelboraf) or per dose cost (Yervoy) of marketed melanoma products in the five major EU markets
  • Table 68: Transparency Commission's ASMR ratings and pricing implications
  • Table 69: Transparency Commission's assessments of melanoma therapies
  • Table 70: G-BA assessment of melanoma therapies
  • Table 71: Reimbursement conditions for melanoma treatments in Italy
  • Table 72: NICE assessment of melanoma therapies
  • Table 73: SMC decisions on melanoma therapies
  • Table 74: Phase III pipeline products in development for melanoma
  • Table 75: Recently discontinued drugs in melanoma
  • Table 76: Binimetinib drug profile
  • Table 77: Binimetinib ongoing Phase III trials in melanoma
  • Table 78: Binimetinib and encorafenib combination Phase II trial data in melanoma
  • Table 79: Encorafenib drug profile
  • Table 80: Encorafenib Phase III trial in melanoma
  • Table 81: Binimetinib and encorafenib combination Phase II trial data in melanoma
Back to Top